Steven Richards

we're going to now sharpen our elbows during diligence, find more than what we likely would have originally, and use that as an opportunity to retrade down. So ultimately, I think it leads to leakage of value in most cases, not all cases. There's been many processes that I've been a part of in the past where we elected to pull

we're going to now sharpen our elbows during diligence, find more than what we likely would have originally, and use that as an opportunity to retrade down. So ultimately, I think it leads to leakage of value in most cases, not all cases. There's been many processes that I've been a part of in the past where we elected to pull

the asset out of market because we knew that we had an inflection point, you know, a big contract or some opportunities where we really hit some tailwinds. And we wanted to get a little bit more time in the rear view mirror so that we would get full credit on a run rate basis for that growth.

the asset out of market because we knew that we had an inflection point, you know, a big contract or some opportunities where we really hit some tailwinds. And we wanted to get a little bit more time in the rear view mirror so that we would get full credit on a run rate basis for that growth.

So it depends on the circumstances, certainly, but I think in an environment where there is uncertainty, the perception is generally going to be that there was something wrong. And yeah, Once you go out to market and you got to go back to the same universe, I think it just presents opportunities to have a less than ideal outcome when it's all said and done.

So it depends on the circumstances, certainly, but I think in an environment where there is uncertainty, the perception is generally going to be that there was something wrong. And yeah, Once you go out to market and you got to go back to the same universe, I think it just presents opportunities to have a less than ideal outcome when it's all said and done.

We're seeing a ton of activity in... pharma and pharma services. I think the outsourced services spend compressed a little bit in the last couple of years with funding kind of being pulled back, but I think we're seeing some uptick in funding into the biotechs, and that's creating an uptick in the broader pharma services landscape.

We're seeing a ton of activity in... pharma and pharma services. I think the outsourced services spend compressed a little bit in the last couple of years with funding kind of being pulled back, but I think we're seeing some uptick in funding into the biotechs, and that's creating an uptick in the broader pharma services landscape.

We're also seeing a much higher need for clinical IT infrastructure, data and analytics. With growing trial complexity, there's a need to accelerate cycle times, increase productivity. and overall reduce the trial timeline, which then improves access to therapies. And the faster you can get to market, the better advantage that you have. And so I think

We're also seeing a much higher need for clinical IT infrastructure, data and analytics. With growing trial complexity, there's a need to accelerate cycle times, increase productivity. and overall reduce the trial timeline, which then improves access to therapies. And the faster you can get to market, the better advantage that you have. And so I think

IT infrastructure and analytics are supporting that. We've seen a big uptick in specialty pharmacy and in home infusion with an aging population, chronic disease prevalence increasing. And in these chronic disease states that are often recurring patients or even lifetime patients,

IT infrastructure and analytics are supporting that. We've seen a big uptick in specialty pharmacy and in home infusion with an aging population, chronic disease prevalence increasing. And in these chronic disease states that are often recurring patients or even lifetime patients,

There's been a really good business model that you can build around specialty pharmacy, which used to have really thin margins. But whether it's autoimmune, neuro, oncology, gastro, rheumatology, dermatology, I think what you're seeing is those that can create a sticky relationship either with the health systems or with the patients or with the drug manufacturers.

There's been a really good business model that you can build around specialty pharmacy, which used to have really thin margins. But whether it's autoimmune, neuro, oncology, gastro, rheumatology, dermatology, I think what you're seeing is those that can create a sticky relationship either with the health systems or with the patients or with the drug manufacturers.

And then you throw a little bit of technology enablement for the case management, clinical management, analytics, etc., You're seeing really, really high outlier type valuations in specialty pharmacy slash home infusion. We've also seen a resurgence in healthcare IT. I come from the health system world myself, so I'm all too familiar with the financial pressures that

And then you throw a little bit of technology enablement for the case management, clinical management, analytics, etc., You're seeing really, really high outlier type valuations in specialty pharmacy slash home infusion. We've also seen a resurgence in healthcare IT. I come from the health system world myself, so I'm all too familiar with the financial pressures that

operators are facing and shifting reimbursement, wage inflation. You know, if you were to draw a baseline or develop a baseline forecast for a health system, it would look like a falling knife. And so every year, Hospital boards have to figure out where they're going to find improvement.

operators are facing and shifting reimbursement, wage inflation. You know, if you were to draw a baseline or develop a baseline forecast for a health system, it would look like a falling knife. And so every year, Hospital boards have to figure out where they're going to find improvement.

And I think healthcare IT is a really good place to improve workflow management, improve revenue cycle, disintermediate cost, improve quality, improve access, all those things that kind of create those sticky revenue streams. So those would be some of the areas that I think are really, really hot right now. Market access also being one of those in the pharma services side of things.

And I think healthcare IT is a really good place to improve workflow management, improve revenue cycle, disintermediate cost, improve quality, improve access, all those things that kind of create those sticky revenue streams. So those would be some of the areas that I think are really, really hot right now. Market access also being one of those in the pharma services side of things.